2000
Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection
Onyeji C, Nicolau D, Nightingale C, Bow L. Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection. Journal Of Antimicrobial Chemotherapy 2000, 46: 429-436. PMID: 10980170, DOI: 10.1093/jac/46.3.429.Peer-Reviewed Original ResearchConceptsGranulocyte colony-stimulating factorG-CSFColony-stimulating factorInfected animalsNeutropenic miceFaecalis infectionDisposition of vancomycinNon-neutropenic animalsEnterococcus faecalis infectionPharmacokinetics of antibioticsInduction of neutropeniaConcentration-time curveEfficacy of gentamicinDose-dependent increaseE. faecalis infectionNeutropenic patientsPharmacokinetic interactionsDosing regimensSame infectionPlasma clearanceUseful adjunctGentamicinInfectionVancomycinMice
1999
Interferon-γ effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils
Onyeji C, Nicolau D, Nightingale C, Bow L. Interferon-γ effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils. International Journal Of Antimicrobial Agents 1999, 11: 31-37. PMID: 10075275, DOI: 10.1016/s0924-8579(98)00085-5.Peer-Reviewed Original ResearchConceptsIFN-gammaHuman neutrophilsMajor therapeutic challengeMultidrug-resistant E. faecalisAnti-enterococcal activityEffective antimicrobial therapyMultidrug-resistant enterococciActivity of gentamicinPotential underlying mechanismsEnterococcus faecalisTherapeutic troughMaximal growth inhibitionTherapeutic challengeSerum troughReactive oxygen intermediatesAntimicrobial therapyUseful adjunctClinical isolatesActivated secretionNeutrophilsPeak levelsGentamicinVancomycinPeak concentrationE. faecalis
1995
Activities of Clarithromycin, Azithromycin, and Ofioxacin in Combination with Liposomal or Unencapsulated Granulocyte-Macrophage Colony-Stimulating Factor against Intramacrophage Mycobacterium avium-Mycobacterium intracellulare
Onyeji C, Nightingale C, Tessier P, Nicolau D, Bow L. Activities of Clarithromycin, Azithromycin, and Ofioxacin in Combination with Liposomal or Unencapsulated Granulocyte-Macrophage Colony-Stimulating Factor against Intramacrophage Mycobacterium avium-Mycobacterium intracellulare. The Journal Of Infectious Diseases 1995, 172: 810-816. PMID: 7658075, DOI: 10.1093/infdis/172.3.810.Peer-Reviewed Original ResearchConceptsMycobacterium avium-Mycobacterium intracellulareGranulocyte-macrophage colony-stimulating factorColony-stimulating factorGM-CSFHuman macrophage infection modelMaximal killing effectTherapeutic peak concentrationsTherapeutic trough concentrationsActivity of clarithromycinEffects of ofloxacinMacrophage infection modelMAI infectionTrough concentrationsSerum troughUseful adjunctClarithromycinAzithromycinInfection modelPeak levelsSignificant augmentationKilling effectPeak concentrationOfloxacinAntimycobacterial activityIntracellulare